BUZZ-HK-listed Hbm climbs to six-week high on licence deal with Pfizer
Hbm Holdings' shares surged 7.8% to a six-week high following a licensing deal with Pfizer. The agreement allows Pfizer global rights to Nona Biosciences' HCAb platform for antibody discovery, with Nona receiving upfront and potential milestone payments. This marks Hbm's largest intraday rise since September 30, with its stock up 676.9% year-to-date.
Shares of Hbm Holdings (2142.HK) jump 7.8% to HK$14.87, their highest point since October 10
Stock on track for a second session of gains, and marks its biggest intraday pct rise since September 30
Co says its unit Nona Biosciences (Suzhou) has entered into a non-exclusive licence agreement with Pfizer (PFE.N) , which aims to accelerate preclinical antibody discovery across a range of potential disease indications
Under the agreement, Pfizer will gain global rights to access Nona’s proprietary HCAb platform to generate fully human heavy chain-only antibodies, while Nona will receive an upfront payment and is eligible for regulatory, clinical, and commercial milestone payments
Nona may collaborate with Pfizer for antibody discovery, development, and engineering, company says
YTD, Hbm stock up 676.9% and Hang Seng Biotech Index (.HSBIO) up 82.6%
